Territory Stories

NT drug trends 2005 : findings from the Illicit Drug Reporting System (IDRS)



NT drug trends 2005 : findings from the Illicit Drug Reporting System (IDRS)


Northern Territory drug trends; E-Journals; PublicationNT; NDARC technical report ; no. 243




Made available via the Publications (Legal Deposit) Act 2004 (NT).; This publication contains may contain links to external sites. These external sites may no longer be active.






Drug abuse -- Northern Territory -- Statistics -- Periodicals; Drug abuse -- Northern Territory -- Periodicals; Drug abuse surveys -- Northern Territory -- Periodicals

Publisher name

National Drug and Alcohol Research Centre, University of New South Wales

Place of publication



NDARC technical report ; no. 243



Copyright owner

Check within Publication or with content Publisher.

Parent handle


Citation address


Page content

51 Figure 37: Number of MS Contin 100mg tablets and Kapanol 100mg capsules prescribed in the NT by year 0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 1998 1999 2000 2001 2002 2003 2004 2005 MS Contin 100mg Kapanol 100mg Source: NT Poisons Control * Prescription data are only collected from community pharmacies. Supplies via non-retail pharmacies such as those at public hospitals, military establishments and remote area dispensaries are not included in these data Figure 38 shows that over the last three years there has been very little change in the number of MS Contin or Kapanol prescriptions. With this Medicare PBS and RPBS data it should be noted that the state/territory is determined according to the address of the pharmacy supplying the item, not the state of residence of the script holder. The month is determined by the date the service was processed by Medicare Australia, not the date of prescribing or the date of supply by the pharmacy. One possible explanation for the change in the IDU pattern of use (decrease in MS Contin and increase in Kapanol) is changes in prescribing practices. However, as can be seen in Figures 37 and 38, there appears to be no changes in the number of tablets/capsules prescribed or number of prescriptions of either brand, and therefore another explanation is warranted.